
{
  "Company Overview": {
    "Name": "Aristo Bio-Tech & Lifescience Ltd",
    "Sector": "Agro Chemicals",
    "Industry": "Pesticides / Agrochemicals - Indian",
    "Business Description": "Manufactures, formulates, supplies, and packages various pesticides, including insecticides, herbicides, fungicides, plant growth regulators, and other agrochemicals. It currently has 257 products registered with CIB&RC for manufacturing and sales, serving both domestic and international customers.",
    "MarketPosition": "Information not explicitly available in provided HTML." 
  },
  "Financial Metrics": {
    "MarketCap": "₹ 94.0 Cr.",
    "CurrentPrice": "₹ 138",
    "High/Low": "₹ 164 / ₹ 53.1",
    "StockPE": "16.0",
    "BookValue": "₹ 56.0",
    "DividendYield": "0.29%",
    "ROCE": "13.2%",
    "ROE": "12.2%",
    "FaceValue": "₹ 10.0",
    "DebtToEquityRatio": "Information not explicitly available in provided HTML." 
  },
  "Performance Trends": {
    "QuarterlyResults": {
      "Sales": {
        "Mar 2022": "73",
        "Sep 2022": "129",
        "Mar 2023": "89",
        "Sep 2023": "133",
        "Mar 2024": "112",
        "Sep 2024": "214"
      },
      "Expenses": {
        "Mar 2022": "72",
        "Sep 2022": "124",
        "Mar 2023": "85",
        "Sep 2023": "128",
        "Mar 2024": "109",
        "Sep 2024": "206"
      },
      "NetProfit": {
        "Mar 2022": "-0",
        "Sep 2022": "3",
        "Mar 2023": "1",
        "Sep 2023": "3",
        "Mar 2024": "1",
        "Sep 2024": "5"
      },
      "EPS": {
        "Mar 2022": "-0.48",
        "Sep 2022": "3.80",
        "Mar 2023": "1.47",
        "Sep 2023": "3.78",
        "Mar 2024": "1.94",
        "Sep 2024": "6.68"
      }
    },
    "AnnualResults": {
      "Sales": {
        "Mar 2016": "57",
        "Mar 2017": "159",
        "Mar 2018": "271",
        "Mar 2019": "202",
        "Mar 2020": "201",
        "Mar 2021": "167",
        "Mar 2022": "166",
        "Mar 2023": "218",
        "Mar 2024": "245"
      },
      "NetProfit": {
        "Mar 2016": "0",
        "Mar 2017": "2",
        "Mar 2018": "4",
        "Mar 2019": "3",
        "Mar 2020": "1",
        "Mar 2021": "1",
        "Mar 2022": "1",
        "Mar 2023": "4",
        "Mar 2024": "6"
      },
      "EPS": {
        "Mar 2016": "4.00",
        "Mar 2017": "18.52",
        "Mar 2018": "37.44",
        "Mar 2019": "5.67",
        "Mar 2020": "2.02",
        "Mar 2021": "2.16",
        "Mar 2022": "2.10",
        "Mar 2023": "5.23",
        "Mar 2024": "8.62"
      }
    },
    "BalanceSheetHighlights": {
      "EquityCapital": {
        "Mar 2016": "1",
        "Mar 2017": "1",
        "Mar 2018": "1",
        "Mar 2019": "5",
        "Mar 2020": "5",
        "Mar 2021": "5",
        "Mar 2022": "5",
        "Mar 2023": "7",
        "Mar 2024": "7",
        "Sep 2024": "7"
      },
      "TotalLiabilities": {
        "Mar 2016": "27",
        "Mar 2017": "87",
        "Mar 2018": "89",
        "Mar 2019": "91",
        "Mar 2020": "88",
        "Mar 2021": "81",
        "Mar 2022": "77",
        "Mar 2023": "100",
        "Mar 2024": "127",
        "Sep 2024": "223"
      },
      "TotalAssets": {
        "Mar 2016": "27",
        "Mar 2017": "87",
        "Mar 2018": "89",
        "Mar 2019": "91",
        "Mar 2020": "88",
        "Mar 2021": "81",
        "Mar 2022": "77",
        "Mar 2023": "100",
        "Mar 2024": "127",
        "Sep 2024": "223"
      }
    },
    "CashFlowSummaries": {
      "CashFromOperatingActivity": {
        "Mar 2016": "-4",
        "Mar 2017": "1",
        "Mar 2018": "8",
        "Mar 2019": "1",
        "Mar 2020": "2",
        "Mar 2021": "7",
        "Mar 2022": "-3",
        "Mar 2023": "8"
      }
    }
  },
  "Ratios": {
    "GrowthRatios": {
      "CompoundedSalesGrowth": {
        "10Years": null,
        "5Years": "4%",
        "3Years": "14%",
        "TTM": "47%"
      },
      "CompoundedProfitGrowth": {
        "10Years": null,
        "5Years": "6%",
        "3Years": "53%",
        "TTM": "64%"
      },
      "StockPriceCAGR": {
        "10Years": null,
        "5Years": null,
        "3Years": null,
        "1Year": "100%"
      }
    },
    "LiquidityRatios": {
      "Information not explicitly available in provided HTML.": null
    },
    "ProfitabilityRatios": {
      "ROCE": {
        "Mar 2016": "31%",
        "Mar 2017": "34%",
        "Mar 2018": "24%",
        "Mar 2019": "14%",
        "Mar 2020": "11%",
        "Mar 2021": "11%",
        "Mar 2022": "16%",
        "Mar 2023": "13%"
      },
      "ROE": {
        "10Years": null,
        "5Years": "12%",
        "3Years": "13%",
        "LastYear": "12%"
      }
    },
    "ValuationRatios": {
      "PE": "16.0",
      "PriceToBook": "Information not explicitly available in provided HTML."
    },
    "OtherRatios": {
      "DebtorDays": {
        "Mar 2016": "92",
        "Mar 2017": "121",
        "Mar 2018": "65",
        "Mar 2019": "77",
        "Mar 2020": "88",
        "Mar 2021": "72",
        "Mar 2022": "73",
        "Mar 2023": "75",
        "Mar 2024": "86"
      },
      "InventoryDays": {
        "Mar 2016": "66",
        "Mar 2017": "67",
        "Mar 2018": "42",
        "Mar 2019": "65",
        "Mar 2020": "47",
        "Mar 2021": "78",
        "Mar 2022": "60",
        "Mar 2023": "57",
        "Mar 2024": "65"
      },
      "DaysPayable": {
        "Mar 2016": "142",
        "Mar 2017": "177",
        "Mar 2018": "85",
        "Mar 2019": "124",
        "Mar 2020": "74",
        "Mar 2021": "93",
        "Mar 2022": "87",
        "Mar 2023": "85",
        "Mar 2024": "112"
      },
      "CashConversionCycle": {
        "Mar 2016": "16",
        "Mar 2017": "11",
        "Mar 2018": "23",
        "Mar 2019": "18",
        "Mar 2020": "61",
        "Mar 2021": "56",
        "Mar 2022": "46",
        "Mar 2023": "48",
        "Mar 2024": "38"
      },
      "WorkingCapitalDays": {
        "Mar 2016": "30",
        "Mar 2017": "26",
        "Mar 2018": "27",
        "Mar 2019": "28",
        "Mar 2020": "37",
        "Mar 2021": "51",
        "Mar 2022": "56",
        "Mar 2023": "56",
        "Mar 2024": "47"
      }
    }
  },
  "PeerComparison": {
    "Peers": [
      {"Name": "P I Industries", "CMP": "3813.75", "PE": "32.60", "MarCap": "57861.50", "DivYld": "0.39", "NPQtr": "508.20", "QtrProfitVar": "5.76", "SalesQtr": "2221.00", "QtrSalesVar": "4.92", "ROCE": "24.00"},
      {"Name": "UPL", "CMP": "504.50", "PE": null, "MarCap": "42601.67", "DivYld": "0.20", "NPQtr": "-585.00", "QtrProfitVar": "-152.09", "SalesQtr": "11090.00", "QtrSalesVar": "9.05", "ROCE": "3.29"},
      {"Name": "Sumitomo Chemi.", "CMP": "525.70", "PE": "54.28", "MarCap": "26240.09", "DivYld": "0.17", "NPQtr": "190.84", "QtrProfitVar": "32.82", "SalesQtr": "971.35", "QtrSalesVar": "7.51", "ROCE": "20.83"},
      {"Name": "Sharda Cropchem", "CMP": "791.70", "PE": "32.80", "MarCap": "7142.76", "DivYld": "0.38", "NPQtr": "42.42", "QtrProfitVar": "253.77", "SalesQtr": "776.89", "QtrSalesVar": "33.77", "ROCE": "4.27"},
      {"Name": "Dhanuka Agritech", "CMP": "1510.15", "PE": "25.42", "MarCap": "6883.01", "DivYld": "0.93", "NPQtr": "117.52", "QtrProfitVar": "15.48", "SalesQtr": "654.28", "QtrSalesVar": "5.88", "ROCE": "26.93"},
      {"Name": "Rallis India", "CMP": "295.65", "PE": "38.59", "MarCap": "5749.47", "DivYld": "0.85", "NPQtr": "98.00", "QtrProfitVar": "20.62", "SalesQtr": "928.00", "QtrSalesVar": "11.54", "ROCE": "11.20"},
      {"Name": "Bharat Rasayan", "CMP": "10440.95", "PE": "30.96", "MarCap": "4338.49", "DivYld": "0.01", "NPQtr": "40.15", "QtrProfitVar": "421.43", "SalesQtr": "327.87", "QtrSalesVar": "24.73", "ROCE": "11.14"}
    ],
    "Median": {
      "CMP": "525.7",
      "PE": "32.8",
      "MarCap": "2106.8",
      "DivYld": "0.2",
      "NPQtr": "26.48",
      "QtrProfitVar": "25.12",
      "SalesQtr": "437.42",
      "QtrSalesVar": "6.7",
      "ROCE": "11.14"
    }
  },
  "OtherInsights": {
    "Pros": [
      "Information not available in provided HTML."
    ],
    "Cons": [
      "The company has delivered a poor sales growth of 3.98% over past five years.",
      "Company has a low return on equity of 13.0% over last 3 years.",
      "Company might be capitalizing the interest cost"
    ],
    "Disclaimer": "The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis."
  },
  "ShareholdingPattern": {
    "Quarterly": {
      "Mar 2023": {
        "Promoters": "73.37%",
        "Public": "26.62%"
      },
      "Sep 2023": {
        "Promoters": "73.37%",
        "Public": "26.63%"
      },
      "Mar 2024": {
        "Promoters": "73.37%",
        "Public": "26.63%"
      },
      "Sep 2024": {
        "Promoters": "73.37%",
        "Public": "26.63%"
      }
    },
    "Yearly": {
      "Mar 2023": {
        "Promoters": "73.37%",
        "Public": "26.62%"
      },
      "Mar 2024": {
        "Promoters": "73.37%",
        "Public": "26.63%"
      },
      "Sep 2024": {
        "Promoters": "73.37%",
        "Public": "26.63%"
      }
    }
  },
  "Documents": {
    "Announcements": [
      {
        "Title": "Outcome of Board Meeting",
        "Date": "14 November 2024",
        "Description": "Aristo Bio-Tech And Lifescience Limited has informed regarding Board meeting held on November 14, 2024."
      },
      {
        "Title": "Financial Result Updates",
        "Date": "14 November 2024",
        "Description": "Aristo Bio-Tech And Lifescience Limited has submitted to the Exchange, the financial results for the period ended September 30, 2024."
      },
      {
        "Title": "Board Meeting Intimation",
        "Date": "13 November 2024",
        "Description": "ARISTO BIO-TECH AND LIFESCIENCE LIMITED has informed about Board Meeting to be held on 14-Nov-2024 to consider and approve the Half Yearly Unaudited Financial results …"
      },
      {
        "Title": "Board Meeting Intimation",
        "Date": "8 November 2024",
        "Description": "ARISTO BIO-TECH AND LIFESCIENCE LIMITED has informed about Board Meeting to be held on 13-Nov-2024 to consider and approve the Half Yearly Unaudited Financial results …"
      },
      {
        "Title": "Quarterly Compliance Report on Corporate governance - within 21 days from the end of the quarter",
        "Date": "14 October 2024",
        "Description": "Aristo Bio-Tech And Lifescience Limited has informed regarding Submission of the Compliance Report on Corporate Governance for the Q_ FY 20__-__"
      }
    ],
    "AnnualReports": [
      {"Year": "2024", "Source": "nse"},
      {"Year": "2023", "Source": "nse"}
    ]
  }
}
